Roles of Infection, Inflammation, and the Immune System in Cholesterol Gallstone Formation

Gastroenterology

Volumn 136, Issue 2, 2009, Pages 425-440

  Maurer, Kirk J ^a,b   Carey, Martin C ^a   Fox, James G ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPID; MUCIN;

BACTERIAL COLONIZATION; BILE DUCT; CHOLECYSTITIS; CHOLESTEROL METABOLISM; CHOLESTEROL STONE; CROHN DISEASE; EPITHELIUM CELL; HELICOBACTER PYLORI; HEPATITIS C; HEPATITIS C VIRUS; HEPATOBILIARY SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INFECTION; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; WILD TYPE;

EID: 58649098779     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.12.031     Document Type: Review

References (194)

1. Carey M.C., and Lamont J.T. Cholesterol gallstone formation. 1. Physical-chemistry of bile and biliary lipid secretion. Prog Liver Dis 10 (1992) 139-163
2. Carey M.C. Pathogenesis of gallstones. Am J Surg 165 (1993) 410-419
3. Paigen B., and Carey M.C. Gallstones. In: King R.A., Rotter J.I., and Motulsky A.G. (Eds). Genetic basis of common diseases. 2nd ed. (2002), Oxford University Press, New York, NY 298-335
4. Carey M.C. Pathogenesis of gallstones. Recenti Prog Med 83 (1992) 379-391
5. Lee S.P., LaMont J.T., and Carey M.C. Role of gallbladder mucus hypersecretion in the evolution of cholesterol gallstones. J Clin Invest 67 (1981) 1712-1723
6. Wang D.Q., Paigen B., and Carey M.C. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: physical-chemistry of gallbladder bile. J Lipid Res 38 (1997) 1395-1411
7. Rosmorduc O., Hermelin B., and Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 120 (2001) 1459-1467
8. Carey M.C., and Cahalane M.J. Whither biliary sludge?. Gastroenterology 95 (1988) 508-523
9. Lee S.P., Hayashi A., and Kim Y.S. Biliary sludge: curiosity or culprit?. Hepatology 20 (1994) 523-525
10. Lee S.P., Maher K., and Nicholls J.F. Origin and fate of biliary sludge. Gastroenterology 94 (1988) 170-176
11. Lammert F., and Matern S. The genetic background of cholesterol gallstone formation: an inventory of human lithogenic genes. Curr Drug Targets Immune Endocr Metabol Disord 5 (2005) 163-170
12. Portincasa P., Moschetta A., and Palasciano G. Cholesterol gallstone disease. Lancet 368 (2006) 230-239
13. van Erpecum K.J. Biliary lipids, water and cholesterol gallstones. Biol Cell 97 (2005) 815-822
14. Wang D.Q., and Afdhal N.H. Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr Gastroenterol Rep 6 (2004) 140-150
15. Katsika D., Grjibovski A., Einarsson C., et al. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology 41 (2005) 1138-1143
16. Maurer K.J., Ihrig M.M., Rogers A.B., et al. Identification of cholelithogenic enterohepatic helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology 128 (2005) 1023-1033
17. Maurer K.J., Rogers A.B., Ge Z., et al. Helicobacter pylori and cholesterol gallstone formation in C57L/J mice: a prospective study. Am J Physiol Gastrointest Liver Physiol 290 (2006) G175-G182
18. Maurer K.J., Rao V.P., Ge Z., et al. T-cell function is critical for murine cholesterol gallstone formation. Gastroenterology 133 (2007) 1304-1315
19. Rege R.V., and Prystowsky J.B. Inflammation and a thickened mucus layer in mice with cholesterol gallstones. J Surg Res 74 (1998) 81-85
20. Baig S.J., Biswas S., Das S., et al. Histopathological changes in gallbladder mucosa in cholelithiasis: correlation with chemical composition of gallstones. Trop Gastroenterol 23 (2002) 25-27
21. Hofmann A.F. Pathogenesis of cholesterol gallstones. J Clin Gastroenterol 10 Suppl 2 (1988) S1-S11
22. van Erpecum K.J., Wang D.Q., Lammert F., et al. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: soluble pronucleating proteins in gallbladder and hepatic biles. J Hepatol 35 (2001) 444-451
23. van Erpecum K.J., Wang D.Q., Moschetta A., et al. Gallbladder histopathology during murine gallstone formation: relation to motility and concentrating function. J Lipid Res 47 (2006) 32-41
24. Strasberg S.M., and Harvey P.R. Biliary cholesterol transport and precipitation: introduction and overview of conference. Hepatology 12 (1990) 1S-5S
25. Auth M.K., Keitzer R.A., Scholz M., et al. Establishment and immunological characterization of cultured human gallbladder epithelial cells. Hepatology 18 (1993) 546-555
26. Rumin S., Loreal O., Drenou B., et al. Patterns of intermediate filaments, VLA integrins and HLA antigens in a new human biliary epithelial cell line sensitive to interferon-gamma. J Hepatol 26 (1997) 1287-1299
27. Harada K., Ohba K., Ozaki S., et al. Peptide antibiotic human beta-defensin-1 and -2 contribute to antimicrobial defense of the intrahepatic biliary tree. Hepatology 40 (2004) 925-932
28. Harada K., Ohira S., Isse K., et al. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab Invest 83 (2003) 1657-1667
29. Reynoso-Paz S., Coppel R.L., Mackay I.R., et al. The immunobiology of bile and biliary epithelium. Hepatology 30 (1999) 351-357
30. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
31. Fritz J.H., and Girardin S.E. How Toll-like receptors and Nod-like receptors contribute to innate immunity in mammals. J Endotoxin Res 11 (2005) 390-394
32. Karin M., Lawrence T., and Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124 (2006) 823-835
33. Banyer J.L., Hamilton N.H., Ramshaw I.A., et al. Cytokines in innate and adaptive immunity. Rev Immunogenet 2 (2000) 359-373
34. Fagarasan S. Intestinal IgA synthesis: a primitive form of adaptive immunity that regulates microbial communities in the gut. Curr Top Microbiol Immunol 308 (2006) 137-153
35. Firestein G.S. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest 114 (2004) 471-474
36. Flajnik M.F., and Du Pasquier L. Evolution of innate and adaptive immunity: can we draw a line?. Trends Immunol 25 (2004) 640-644
37. Harada K., Isse K., Sato Y., et al. Endotoxin tolerance in human intrahepatic biliary epithelial cells is induced by upregulation of IRAK-M. Liver Int 26 (2006) 935-942
38. Chen X.M., O'Hara S.P., Nelson J.B., et al. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB. J Immunol 175 (2005) 7447-7456
39. Rogers K.A., Rogers A.B., Leav B.A., et al. MyD88-dependent pathways mediate resistance to Cryptosporidium parvum infection in mice. Infect Immun 74 (2006) 549-556
40. Aoki C.A., Bowlus C.L., and Gershwin M.E. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 4 (2005) 137-143
41. Adams D.H., and Afford S.C. The role of cholangiocytes in the development of chronic inflammatory liver disease. Front Biosci 7 (2002) e276-e285
42. Adams D.H., and Afford S.C. Effector mechanisms of nonsuppurative destructive cholangitis in graft-versus-host disease and allograft rejection. Semin Liver Dis 25 (2005) 281-297
43. Bloom S., Fleming K., and Chapman R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut 36 (1995) 604-609
44. Howell C.D., Li J., and Chen W. Role of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 during nonsuppurative destructive cholangitis in a mouse graft-versus-host disease model. Hepatology 29 (1999) 766-776
45. Korlipara L.V., Leon M.P., Rix D.A., et al. Development of a flow cytometric assay to quantify lymphocyte adhesion to cytokine-stimulated human endothelial and biliary epithelial cells. J Immunol Methods 191 (1996) 121-130
46. Kaetzel C.S. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev 206 (2005) 83-99
47. Mostov K.E. Transepithelial transport of immunoglobulins. Annu Rev Immunol 12 (1994) 63-84
48. Norderhaug I.N., Johansen F.E., Schjerven H., et al. Regulation of the formation and external transport of secretory immunoglobulins. Crit Rev Immunol 19 (1999) 481-508
49. Rojas R., and Apodaca G. Immunoglobulin transport across polarized epithelial cells. Nat Rev Mol Cell Biol 3 (2002) 944-955
50. Dickinson B.L., Claypool S.M., D'Angelo J.A., et al. Ca2+-dependent calmodulin binding to FcRn affects immunoglobulin G transport in the transcytotic pathway. Mol Biol Cell 19 (2008) 414-423
51. Blumberg R.S., Koss T., Story C.M., et al. A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J Clin Invest 95 (1995) 2397-2402
52. Brown W.R., and Kloppel T.M. The liver and IgA: immunological, cell biological and clinical implications. Hepatology 9 (1989) 763-784
53. McQueen C.E., Boedeker E.C., Le M., et al. Mucosal immune response to RDEC-1 infection: study of lamina propria antibody-producing cells and biliary antibody. Infect Immun 60 (1992) 206-212
54. Savard C.E., Blinman T.A., Choi H.S., et al. Expression of cytokine and chemokine mRNA and secretion of tumor necrosis factor-alpha by gallbladder epithelial cells: response to bacterial lipopolysaccharides. BMC Gastroenterol 2 (2002) 23
55. Shi J.S., Zhou L.S., Han Y., et al. Expression of tumor necrosis factor and its receptor in gallstone and gallbladder carcinoma tissue. Hepatobiliary Pancreat Dis Int 3 (2004) 448-452
56. Rege R.V. Inflammatory cytokines alter human gallbladder epithelial cell absorption/secretion. J Gastrointest Surg 4 (2000) 185-192
57. Prystowsky J.B., and Rege R.V. Interleukin-1 mediates guinea pig gallbladder inflammation in vivo. J Surg Res 71 (1997) 123-126
58. Chung-Park M., Kim B., Marmolya G., et al. Acalculus lymphoeosinophilic cholecystitis associated with interleukin-2 and lymphokine-activated killer cell therapy. Arch Pathol Lab Med 114 (1990) 1073-1075
59. Dickey K.W., Barth R.A., and Stewart J.A. Recurrent transient gallbladder wall thickening associated with interleukin-2 chemotherapy. J Clin Ultrasound 21 (1993) 58-61
60. Powell F.C., Spooner K.M., Shawker T.H., et al. Symptomatic interleukin-2-induced cholecystopathy in patients with HIV infection. AJR Am J Roentgenol 163 (1994) 117-121
61. Mori M., and Miyazaki K. Factors affecting morphogenesis of rabbit gallbladder epithelial cells cultured in collagen gels. Cell Tissue Res 300 (2000) 331-344
62. Koninger J., di Mola F.F., Di Sebastiano P., et al. Transforming growth factor-beta pathway is activated in cholecystolithiasis. Langenbecks Arch Surg 390 (2005) 21-28
63. Hemming J.M., Guarraci F.A., Firth T.A., et al. Actions of histamine on muscle and ganglia of the guinea pig gallbladder. Am J Physiol Gastrointest Liver Physiol 279 (2000) G622-G630
64. He X.S., Ansari A.A., Ridgway W.M., et al. New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis. Cell Immunol 239 (2006) 1-13
65. Alba L.M., Angulo P., and Lindor K.D. Primary sclerosing cholangitis. Minerva Gastroenterol Dietol 48 (2002) 99-113
66. Cullen S., and Chapman R. Primary sclerosing cholangitis. Autoimmun Rev 2 (2003) 305-312
67. Koukoulis G.K., Shen J., Karademir S., et al. Cholangiocytic apoptosis in chronic ductopenic rejection. Hum Pathol 32 (2001) 823-827
68. Harvey P.R., Upadhya G.A., and Strasberg S.M. Immunoglobulins as nucleating proteins in the gallbladder bile of patients with cholesterol gallstones. J Biol Chem 266 (1991) 13996-14003
69. Harvey P.R., and Upadhya G.A. A rapid, simple high capacity cholesterol crystal growth assay. J Lipid Res 36 (1995) 2054-2058
70. Upadhya G.A., Harvey P.R., and Strasberg S.M. Effect of human biliary immunoglobulins on the nucleation of cholesterol. J Biol Chem 268 (1993) 5193-5200
71. Paigen B., Schork N.J., Svenson K.L., et al. Quantitative trait loci mapping for cholesterol gallstones in AKR/J and C57L/J strains of mice. Physiol Genomics 4 (2000) 59-65
72. Miquel J.F., Nunez L., Amigo L., et al. Cholesterol saturation, not proteins or cholecystitis, is critical for crystal formation in human gallbladder bile. Gastroenterology 114 (1998) 1016-1023
73. Lipsett P.A., Hildreth J., Kaufman H.S., et al. Human gallstones contain pronucleating nonmucin glycoproteins that are immunoglobulins. Ann Surg 219 (1994) 25-33
74. Andrianifahanana M., Moniaux N., and Batra S.K. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta 1765 (2006) 189-222
75. Lammert F., Wang D.Q., Wittenburg H., et al. Lith genes control mucin accumulation, cholesterol crystallization, and gallstone formation in A/J and AKR/J inbred mice. Hepatology 36 (2002) 1145-1154
76. LaMont J.T., Smith B.F., and Moore J.R. Role of gallbladder mucin in pathophysiology of gallstones. Hepatology 4 (1984) 51S-56S
77. Lee K.T., and Liu T.S. Mucin gene expression in gallbladder epithelium. J Formos Med Assoc 101 (2002) 762-768
78. Wang H.H., Afdhal N.H., Gendler S.J., et al. Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation. J Lipid Res 45 (2004) 438-447
79. Wang H.H., Afdhal N.H., Gendler S.J., et al. Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice. Gastroenterology 131 (2006) 210-222
80. Afdhal N.H., Niu N., Gantz D., et al. Bovine gallbladder mucin accelerates cholesterol monohydrate crystal growth in model bile. Gastroenterology 104 (1993) 1515-1523
81. Levy P.F., Smith B.F., and LaMont J.T. Human gallbladder mucin accelerates nucleation of cholesterol in artificial bile. Gastroenterology 87 (1984) 270-275
82. Smith B.F. Gallbladder mucin as a pronucleating agent for cholesterol monohydrate crystals in bile. Hepatology 12 (1990) 183S-186S discussion 186S-188S
83. Yamasaki T., Chijiiwa K., and Endo M. Isolation of mucin from human hepatic bile and its induced effects on precipitation of cholesterol and calcium carbonate in vitro. Dig Dis Sci 38 (1993) 909-915
84. Zen Y., Harada K., Sasaki M., et al. Lipopolysaccharide induces overexpression of MUC2 and MUC5AC in cultured biliary epithelial cells: possible key phenomenon of hepatolithiasis. Am J Pathol 161 (2002) 1475-1484
85. Ikeda H., Sasaki M., Ishikawa A., et al. Interaction of Toll-like receptors with bacterial components induces expression of CDX2 and MUC2 in rat biliary epithelium in vivo and in culture. Lab Invest 87 (2007) 559-571
86. Sakamoto H., Mutoh H., Ido K., et al. A close relationship between intestinal metaplasia and Cdx2 expression in human gallbladders with cholelithiasis. Hum Pathol 38 (2007) 66-71
87. Choi J., Klinkspoor J.H., Yoshida T., et al. Lipopolysaccharide from Escherichia coli stimulates mucin secretion by cultured dog gallbladder epithelial cells. Hepatology 29 (1999) 1352-1357
88. Finzi L., Barbu V., Burgel P.R., et al. MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder. Am J Pathol 169 (2006) 2031-2041
89. Little T.E., Madani H., Lee S.P., et al. Lipid vesicle fusion induced by phospholipase C activity in model bile. J Lipid Res 34 (1993) 211-217
90. Offner G.D., Gong D., and Afdhal N.H. Identification of a 130-kilodalton human biliary concanavalin A binding protein as aminopeptidase N. Gastroenterology 106 (1994) 755-762
91. Zhou H., Chen B., Li R.X., et al. Large-scale identification of human biliary proteins from a cholesterol stone patient using a proteomic approach. Rapid Commun Mass Spectrom 19 (2005) 3569-3578
92. Moschetta A., Bookout A.L., and Mangelsdorf D.J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 10 (2004) 1352-1358
93. Lyons M.A., and Wittenburg H. Susceptibility to cholesterol gallstone formation: Evidence that LITH genes also encode immune-related factors. Biochim Biophys Acta 1761 (2006) 1133-1147
94. Portincasa P., Di Ciaula A., Vendemiale G., et al. Gallbladder motility and cholesterol crystallization in bile from patients with pigment and cholesterol gallstones. Eur J Clin Invest 30 (2000) 317-324
95. Lee S.P. Lessons from experimental cholelithiasis: gallbladder and mucosa, nonsteroidal antiinflammatory drugs, and gallstones. Gastroenterology 101 (1991) 857-860
96. Xiao Z.L., Amaral J., Biancani P., et al. Impaired cytoprotective function of muscle in human gallbladders with cholesterol stones. Am J Physiol Gastrointest Liver Physiol 288 (2005) G525-G532
97. van de Heijning B.J., van de Meeberg P.C., Portincasa P., et al. Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones. Dig Dis Sci 44 (1999) 190-196
98. Haigh W.G., and Lee S.P. Identification of oxysterols in human bile and pigment gallstones. Gastroenterology 121 (2001) 118-123
99. Seo D.W., Choi H.S., Lee S.P., et al. Oxysterols from human bile induce apoptosis of canine gallbladder epithelial cells in monolayer culture. Am J Physiol Gastrointest Liver Physiol 287 (2004) G1247-G1256
100. Lee S.P., Carey M.C., and LaMont J.T. Aspirin prevention of cholesterol gallstone formation in prairie dogs. Science 211 (1981) 1429-1431
101. Adamek H.E., Buttmann A., Weber J., et al. Can aspirin prevent gallstone recurrence after successful extracorporeal shockwave lithotripsy?. Scand J Gastroenterol 29 (1994) 355-359
102. Broomfield P.H., Chopra R., Sheinbaum R.C., et al. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med 319 (1988) 1567-1572
103. Cohen B.I., Mosbach E.H., Ayyad N., et al. Aspirin does not inhibit cholesterol cholelithiasis in two established animal models. Gastroenterology 101 (1991) 1109-1116
104. Kurata J.H., Marks J., and Abbey D. One gram of aspirin per day does not reduce risk of hospitalization for gallstone disease. Dig Dis Sci 36 (1991) 1110-1115
105. Li Y.F., Russell D.H., Myers S.I., et al. Gallbladder contractility in aspirin- and cholesterol-fed prairie dogs. Gastroenterology 106 (1994) 1662-1667
106. Araki Y., Andoh A., Bamba H., et al. The cytotoxicity of hydrophobic bile acids is ameliorated by more hydrophilic bile acids in intestinal cell lines IEC-6 and Caco-2. Oncol Rep 10 (2003) 1931-1936
107. Yui S., Saeki T., Kanamoto R., et al. Characteristics of apoptosis in HCT116 colon cancer cells induced by deoxycholic acid. J Biochem (Tokyo) 138 (2005) 151-157
108. Lamireau T., Zoltowska M., Levy E., et al. Effects of bile acids on biliary epithelial cells: proliferation, cytotoxicity, and cytokine secretion. Life Sci 72 (2003) 1401-1411
109. Kano M., Shoda J., Irimura T., et al. Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones. Hepatology 28 (1998) 302-313
110. Maurer K.J. A systematic evaluation of the role of infection, immunity and inflammation in cholesterol gallstone pathogenesis. [doctoral thesis] (2007), Massachusetts Institute of Technology, Cambridge, MA 159
111. Paumgartner G., Pauletzki J., and Sackmann M. Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand J Gastroenterol Suppl 204 (1994) 27-31
112. Paumgartner G., and Sauerbruch T. Gallstones: pathogenesis. Lancet 338 (1991) 1117-1121
113. Henkel A., Wei Z., Cohen D.E., et al. Mice overexpressing hepatic Abcb11 rapidly develop cholesterol gallstones. Mamm Genome 16 (2005) 903-908
114. Portincasa P., van de Meeberg P., van Erpecum K.J., et al. An update on the pathogenesis and treatment of cholesterol gallstones. Scand J Gastroenterol Suppl 223 (1997) 60-69
115. Merselis Jr. J.G., Kaye D., Connolly C.S., et al. The typhoid carrier state: quantitative bacteriology and preliminary observations on therapy. East Afr Med J 41 (1964) 219-227
116. Rains A.J., Barson G.J., Crawford N., et al. A chemical and bacteriological study of gallstones. The presence of an actinomycete. Lancet 2 (1960) 614-618
117. Scott A.J., and Khan G.A. Origin of bacteria in bileduct bile. Lancet 2 (1967) 790-792
118. Salen G. Gallstone dissolution therapy with ursodiol. Efficacy and safety. Dig Dis Sci 34 (1989) 39S-43S
119. Hellstern A., Leuschner U., Benjaminov A., et al. Dissolution of gallbladder stones with methyl tert-butyl ether and stone recurrence: a European survey. Dig Dis Sci 43 (1998) 911-920
120. Pauletzki J., Holl J., Sackmann M., et al. Gallstone recurrence after direct contact dissolution with methyl tert-butyl ether. Dig Dis Sci 40 (1995) 1775-1781
121. Lamont J.T., and Carey M.C. Cholesterol gallstone formation. 2. Pathobiology and pathomechanics. Prog Liver Dis 10 (1992) 165-191
122. Cahalane M.J., Neubrand M.W., and Carey M.C. Physical-chemical pathogenesis of pigment gallstones. Semin Liver Dis 8 (1988) 317-328
123. Lee D.K., Tarr P.I., Haigh W.G., et al. Bacterial DNA in mixed cholesterol gallstones. Am J Gastroenterol 94 (1999) 3502-3506
124. Swidsinski A., and Lee S.P. The role of bacteria in gallstone pathogenesis. Front Biosci 6 (2001) E93-E103
125. Swidsinski A., Ludwig W., Pahlig H., et al. Molecular genetic evidence of bacterial colonization of cholesterol gallstones. Gastroenterology 108 (1995) 860-864
126. Wu X.T., Xiao L.J., Li X.Q., et al. Detection of bacterial DNA from cholesterol gallstones by nested primers polymerase chain reaction. World J Gastroenterol 4 (1998) 234-237
127. Kawai M., Iwahashi M., Uchiyama K., et al. Gram-positive cocci are associated with the formation of completely pure cholesterol stones. Am J Gastroenterol 97 (2002) 83-88
128. Vitetta L., Sali A., Moritz V., et al. Bacteria and gallstone nucleation. Aust N Z J Surg 59 (1989) 571-577
129. Vitetta L., Best S.P., and Sali A. Single and multiple cholesterol gallstones and the influence of bacteria. Med Hypotheses 55 (2000) 502-506
130. Whiting M.J., and Watts J.M. Cholesterol gallstone pathogenesis: a study of potential nucleating agents for cholesterol crystal formation in bile. Clin Sci (Lond) 68 (1985) 589-596
131. Farshad S., Alborzi A., Malek Hosseini S.A., et al. Identification of Helicobacter pylori DNA in Iranian patients with gallstones. Epidemiol Infect 132 (2004) 1185-1189
132. Monstein H.J., Jonsson Y., Zdolsek J., et al. Identification of Helicobacter pylori DNA in human cholesterol gallstones. Scand J Gastroenterol 37 (2002) 112-119
133. Myung S.J., Kim M.H., Shim K.N., et al. Detection of Helicobacter pylori DNA in human biliary tree and its association with hepatolithiasis. Dig Dis Sci 45 (2000) 1405-1412
134. Silva C.P., Pereira-Lima J.C., Oliveira A.G., et al. Association of the presence of Helicobacter in gallbladder tissue with cholelithiasis and cholecystitis. J Clin Microbiol 41 (2003) 5615-5618
135. Mathai E., Arora A., Cafferkey M., et al. The effect of bile acids on the growth and adherence of Helicobacter pylori. Aliment Pharmacol Ther 5 (1991) 653-658
136. Worku M.L., Karim Q.N., Spencer J., et al. Chemotactic response of Helicobacter pylori to human plasma and bile. J Med Microbiol 53 (2004) 807-811
137. Kawaguchi M., Saito T., Ohno H., et al. Bacteria closely resembling Helicobacter pylori detected immunohistologically and genetically in resected gallbladder mucosa. J Gastroenterol 31 (1996) 294-298
138. O'Rourke J.L., Solnick J.V., Neilan B.A., et al. Description of 'Candidatus Helicobacter heilmannii' based on DNA sequence analysis of 16S rRNA and urease genes. Int J Syst Evol Microbiol 54 (2004) 2203-2211
139. Avenaud P., Marais A., Monteiro L., et al. Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma. Cancer 89 (2000) 1431-1439
140. Fox J. Enterohepatic Helicobacters: natural and experimental models. Ital J Gastroenterol Hepatol 30 Suppl 3 (1998) S264-S269
141. Solnick J.V., and Schauer D.B. Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev 14 (2001) 59-97
142. Fox J.G., Dewhirst F.E., Shen Z., et al. Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology 114 (1998) 755-763
143. Matsukura N., Yokomuro S., Yamada S., et al. Association between Helicobacter bilis in bile and biliary tract malignancies: H. bilis in bile from Japanese and Thai patients with benign and malignant diseases in the biliary tract. Jpn J Cancer Res 93 (2002) 842-847
144. Belzer C., Kusters J.G., Kuipers E.J., et al. Urease induced calcium precipitation by Helicobacter species may initiate gallstone formation. Gut 55 (2006) 1678-1679
145. Sanabria J.R., Upadhya G.A., Harvey R.P., et al. Diffusion of substances into human cholesterol gallstones. Gastroenterology 106 (1994) 749-754
146. Bruce I.J. Nucleic acid amplification mediated microbial identification. Sci Prog 77 (1993) 183-206
147. Davis R.E., Jomantiene R., Kalvelyte A., et al. Differential amplification of sequence heterogeneous ribosomal RNA genes and classification of the 'Fragaria multicipita' phytoplasma. Microbiol Res 158 (2003) 229-236
148. King S., McCord B.R., and Riefler R.G. Capillary electrophoresis single-strand conformation polymorphism analysis for monitoring soil bacteria. J Microbiol Methods 60 (2005) 83-92
149. Dutta U., Garg P.K., Kumar R., et al. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol 95 (2000) 784-787
150. Lai C.W., Chan R.C., Cheng A.F., et al. Common bile duct stones: a cause of chronic salmonellosis. Am J Gastroenterol 87 (1992) 1198-1199
151. Prouty A.M., Schwesinger W.H., and Gunn J.S. Biofilm formation and interaction with the surfaces of gallstones by Salmonella spp. Infect Immun 70 (2002) 2640-2649
152. Prouty A.M., and Gunn J.S. Comparative analysis of Salmonella enterica serovar Typhimurium biofilm formation on gallstones and on glass. Infect Immun 71 (2003) 7154-7158
153. Bini E.J., and McGready J. Prevalence of gallbladder disease among persons with hepatitis C virus infection in the United States. Hepatology 41 (2005) 1029-1036
154. Chang T.S., Lo S.K., Shyr H.Y., et al. Hepatitis C virus infection facilitates gallstone formation. J Gastroenterol Hepatol 20 (2005) 1416-1421
155. Elzouki A.N., Nilsson S., Nilsson P., et al. The prevalence of gallstones in chronic liver disease is related to degree of liver dysfunction. Hepatogastroenterology 46 (1999) 2946-2950
156. Sheen I.S., and Liaw Y.F. The prevalence and incidence of cholecystolithiasis in patients with chronic liver diseases: a prospective study. Hepatology 9 (1989) 538-540
157. Loriot M.A., Bronowicki J.P., Lagorce D., et al. Permissiveness of human biliary epithelial cells to infection by hepatitis C virus. Hepatology 29 (1999) 1587-1595
158. Nouri Aria K.T., Sallie R., Sangar D., et al. Detection of genomic and intermediate replicative strands of hepatitis C virus in liver tissue by in situ hybridization. J Clin Invest 91 (1993) 2226-2234
159. Bargiggia S., Maconi G., Elli M., et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 36 (2003) 417-420
160. Fraquelli M., Losco A., Visentin S., et al. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med 161 (2001) 2201-2204
161. Kratzer W., Haenle M.M., Mason R.A., et al. Prevalence of cholelithiasis in patients with chronic inflammatory bowel disease. World J Gastroenterol 11 (2005) 6170-6175
162. Whorwell P.J., Hawkins R., Dewbury K., et al. Ultrasound survey of gallstones and other hepatobiliary disorders in patients with Crohn's disease. Dig Dis Sci 29 (1984) 930-933
163. Hutchinson R., Tyrrell P.N., Kumar D., et al. Pathogenesis of gall stones in Crohn's disease: an alternative explanation. Gut 35 (1994) 94-97
164. Pereira S.P., Bain I.M., Kumar D., et al. Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. Aliment Pharmacol Ther 17 (2003) 923-933
165. Freudenberg F., and Carey M.C. Hepatobiliary manifestations in inflammatory bowel disease. In: Blumberg R.S., Gangl A., and Manns M.P. (Eds). Gut-Liver Interactions: Basic and Clinical Concepts (2005), Springer, Dordrecht, The Netherlands 165-176
166. Lapidus A., and Einarsson C. Bile composition in patients with ileal resection due to Crohn's disease. Inflamm Bowel Dis 4 (1998) 89-94
167. Lapidus A., and Einarsson K. Effects of ileal resection on biliary lipids and bile acid composition in patients with Crohn's disease. Gut 32 (1991) 1488-1491
168. Hofmann A.F. Medical dissolution of gallstones by oral bile acid therapy. Am J Surg 158 (1989) 198-204
169. Jungst D., Brenner G., Pratschke E., et al. Low-dose ursodeoxycholic acid prolongs cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones. J Hepatol 8 (1989) 1-6
170. Bamias G., Sugawara K., Pagnini C., et al. The Th1 immune pathway as a therapeutic target in Crohn's disease. Curr Opin Investig Drugs 4 (2003) 1279-1286
171. Heller F., Florian P., Bojarski C., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129 (2005) 550-564
172. Heller F., Fuss I.J., Nieuwenhuis E.E., et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17 (2002) 629-638
173. Feingold K.R., Pollock A.S., Moser A.H., et al. Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J Lipid Res 36 (1995) 1474-1482
174. Hardardottir I., Grunfeld C., and Feingold K.R. Effects of endotoxin on lipid metabolism. Biochem Soc Trans 23 (1995) 1013-1018
175. Hardardottir I., Moser A.H., Memon R., et al. Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res 13 (1994) 161-166
176. Khovidhunkit W., Kim M.S., Memon R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45 (2004) 1169-1196
177. Memon R.A., Shechter I., Moser A.H., et al. Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters. J Lipid Res 38 (1997) 1620-1629
178. Feingold K.R., Hardardottir I., Memon R., et al. Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J Lipid Res 34 (1993) 2147-2158
179. Yoo J.Y., and Desiderio S. Innate and acquired immunity intersect in a global view of the acute-phase response. Proc Natl Acad Sci U S A 100 (2003) 1157-1162
180. Mookerjea S., Coolbear T., and Sarkar M.L. Key role of dolichol phosphate in glycoprotein biosynthesis. Can J Biochem Cell Biol 61 (1983) 1032-1040
181. Sarkar M., and Mookerjea S. Differential effect of inflammation and dexamethasone on dolichol and dolichol phosphate synthesis. Biochem Cell Biol 66 (1988) 1265-1269
182. Auerbach B.J., and Parks J.S. Lipoprotein abnormalities associated with lipopolysaccharide-induced lecithin: cholesterol acyltransferase and lipase deficiency. J Biol Chem 264 (1989) 10264-10270
183. Ettinger W.H., Miller L.D., Albers J.J., et al. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys. J Lipid Res 31 (1990) 1099-1107
184. Sammalkorpi K., Valtonen V., Kerttula Y., et al. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 37 (1988) 859-865
185. Ettinger W.H., Varma V.K., Sorci-Thomas M., et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb 14 (1994) 8-13
186. Schectman G., Kaul S., Mueller R.A., et al. The effect of interferon on the metabolism of LDLs. Arterioscler Thromb 12 (1992) 1053-1062
187. Feingold K.R., Spady D.K., Pollock A.S., et al. Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J Lipid Res 37 (1996) 223-228
188. Memon R.A., Moser A.H., Shigenaga J.K., et al. In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response. potential role of hepatocyte nuclear factor-1. J Biol Chem 276 (2001) 30118-30126
189. Green R.M., Beier D., and Gollan J.L. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 111 (1996) 193-198
190. Hartmann G., Cheung A.K., and Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther 303 (2002) 273-281
191. Moseley R.H., Wang W., Takeda H., et al. Effect of endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. Am J Physiol 271 (1996) G137-G146
192. Trauner M., Arrese M., Lee H., et al. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. J Clin Invest 101 (1998) 2092-2100
193. Vos T.A., Hooiveld G.J., Koning H., et al. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 28 (1998) 1637-1644
194. Tygstrup N., Bangert K., Ott P., et al. Messenger RNA profiles in liver injury and stress: a comparison of lethal and nonlethal rat models. Biochem Biophys Res Commun 290 (2002) 518-525